Psagot Investment House Ltd. bought a new stake in shares of BioTelemetry, Inc. (NASDAQ:BEAT) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 22,350 shares of the medical research company’s stock, valued at approximately $738,000. Psagot Investment House Ltd. owned approximately 0.07% of BioTelemetry at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Winslow Evans & Crocker Inc. acquired a new position in BioTelemetry in the 3rd quarter worth $109,000. Pinebridge Investments L.P. lifted its holdings in BioTelemetry by 2.0% in the 2nd quarter. Pinebridge Investments L.P. now owns 3,775 shares of the medical research company’s stock worth $126,000 after buying an additional 75 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in BioTelemetry by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 4,177 shares of the medical research company’s stock worth $140,000 after buying an additional 626 shares in the last quarter. US Bancorp DE acquired a new position in BioTelemetry in the 2nd quarter worth $145,000. Finally, Sei Investments Co. lifted its holdings in BioTelemetry by 242.8% in the 2nd quarter. Sei Investments Co. now owns 5,783 shares of the medical research company’s stock worth $193,000 after buying an additional 4,096 shares in the last quarter. Institutional investors and hedge funds own 82.23% of the company’s stock.

A number of equities analysts have commented on the stock. Sidoti reiterated a “buy” rating and issued a $49.00 price objective (up previously from $42.00) on shares of BioTelemetry in a report on Thursday, August 10th. BidaskClub upgraded shares of BioTelemetry from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 16th. Dougherty & Co reiterated a “buy” rating and issued a $40.00 price objective on shares of BioTelemetry in a report on Wednesday, November 8th. Zacks Investment Research upgraded shares of BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $39.00 price objective on the stock in a report on Friday, August 11th. Finally, SunTrust Banks assumed coverage on shares of BioTelemetry in a report on Monday, October 23rd. They issued a “buy” rating and a $41.00 price objective on the stock. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. BioTelemetry currently has a consensus rating of “Buy” and a consensus price target of $42.86.

Shares of BioTelemetry, Inc. (BEAT) opened at $26.80 on Thursday. The firm has a market cap of $870.16, a PE ratio of 36.78, a PEG ratio of 1.68 and a beta of 0.53. BioTelemetry, Inc. has a 1 year low of $20.00 and a 1 year high of $39.20. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.60 and a quick ratio of 1.48.

BioTelemetry (NASDAQ:BEAT) last released its earnings results on Tuesday, November 7th. The medical research company reported $0.16 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by ($0.09). The company had revenue of $81.02 million during the quarter, compared to the consensus estimate of $82.10 million. BioTelemetry had a return on equity of 13.66% and a net margin of 16.10%. BioTelemetry’s revenue for the quarter was up 52.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.21 EPS. equities research analysts forecast that BioTelemetry, Inc. will post 0.83 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Psagot Investment House Ltd. Takes Position in BioTelemetry, Inc. (BEAT)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/12/07/psagot-investment-house-ltd-takes-position-in-biotelemetry-inc-beat.html.

BioTelemetry Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry, Inc. (NASDAQ:BEAT).

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.